The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index; 4 of the 10 sources its claims cite were checked for support.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Open accessAbstract
BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: CAR-positive (CAR+) T cells. The primary end point was an overall response (partial response or better); a key secondary end point was a complete response or better (comprising complete and stringent complete responses). RESULTS: nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better. The median progression-free survival was 8.8 months (95% confidence interval, 5.6 to 11.6). Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%). Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred. Cellular kinetic analysis confirmed CAR+ T cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 10 cited sources checked · 2 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“The B-cell maturation antigen (BCMA)-directed CAR T cell idecabtagene vicleucel (ide-cel, also called bb2121) showed promising efficacy in a phase 1 study involving patients with relapsed or refractory myeloma.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > D
What the sources say
- Supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. source
The Methods identify bb2121 as an anti-BCMA CAR T-cell therapy studied in a phase 1 trial involving patients with relapsed or refractory multiple myeloma. The Discussion reports an 85% clinical response rate, supporting the characterization of its efficacy as promising. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Supportedcites [5] 5. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727-38. source
The Methods and Discussion describe patients with triple-class refractory myeloma who were heavily pretreated, with a median of seven previous regimens. The Efficacy section reports median progression-free survival of 3.7 months with selinexor plus dexamethasone. This citation supports the selinexor result; the separate belantamab result is not attributed to this paper. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [17] 17. Lonial S, Lee HC, Badros A, et al. Belan- tamab mafodotin for relapsed or refracto- ry multiple myeloma (DREAMM-2): a two- arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207-21. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observed toxic effects were consistent with those in previous reports.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. sourceExperimental — accuracy not yet measured
The Results (Safety; page unavailable) document the observed toxic effects. The Discussion compares them with previous studies, but reports a lower incidence of severe cytokine release syndrome with bb2121 and cautions that cross-study comparisons are complicated. It does not establish that the toxic effects were generally consistent with previous reports. (LLM, conf=0.82)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Duration of undetectable sBCMA correlated with response duration, and clearance of sBCMA at month 2 was associated with longer progression-free survival (Fig. S5E and S5F).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with peak levels higher in patients having cytokine release syndrome of grade 3 or higher (Fig. S6).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a somewhat higher frequency and somewhat greater depth of response were observed at the 450 × 10 6 dose (response in 81% of the pa-tients and complete response or better in 39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, 110 of 112 tumor samples (98%) expressed BCMA, with 109 having at least 50% BCMA-positive plasma cells, and all the patients had detectable levels of sBCMA.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedn = 112Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A response was observed in 73% of the treated patients, and a complete response or better was observed in 33%;”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline cytokine levels were not associated with higher-grade cytokine release syndrome or neurotoxic effects.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with an incidence of response to bridging therapy of 4%”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 12
- It may state two separate claims as one. 32
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, CD19 epitope loss is reported to be a relatively common escape mechanism after treatment with CD19-directed CAR T-cell therapy, especially in patients with acute leukemia.18,19”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [18] 18. Cheng J, Zhao L, Zhang Y, et al. Un- derstanding the mechanisms of resis- tance to CAR T-cell therapy in malignan- cies. Front Oncol 2019; 9: 1237. sourceExperimental — accuracy not yet measured
The Tumor Factors section reports that loss of the targeted CD19 epitope enabled escape after anti-CD19 CAR T-cell therapy in relapsed B-ALL. It also reports that target-antigen-negative relapse accounts for approximately 9–25% of B-ALL relapses, but does not establish that epitope loss specifically is relatively common or more common in acute leukemia than in other malignancies. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [19] 19. Badar T, Shah NN. Chimeric antigen receptor T cell therapy for acute lympho- blastic leukemia. Curr Treat Options On- col 2020; 21: 16. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with persistent grade 3 or 4 neutropenia (52 patients) or thrombocytopenia (62 patients) 1 month after infusion, the median time to recovery to grade 2 or lower was 1.9 months (range, 1.2 to 5.6) and 2.1 months (range, 1.2 to 13.8), respectively”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 52Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median progression-free survival was 8.8 months overall (95% CI, 5.6 to 11.6), 12.1 months (95% CI, 8.8 to 12.3) at the 450 × 10 6 dose, and 20.2 months (95% CI, 12.3 to could not be estimated) in patients having a complete or stringent complete response”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 128 treated patients had received a median of 6 previous antimyeloma regimens (range, 3 to 16), and 120 (94%) had received previous autologous hematopoietic stem-cell transplants (Table 1).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although high interpatient variability was observed at all doses, upper quartiles of exposure (area under the curve of the transgene level from time of dose to 28 days [AUC 0-28 days ]) were observed more frequently at the 450 × 10 6 dose (Fig. 3B).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among treated patients, 5 were positive for antidrug antibodies before infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline sBCMA levels were elevated in treated patients and de-creased rapidly after infusion in patients who had a response, with nadir values achieved within 3 months (Fig. 3A and Fig. S5B and S5C).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred.”
- Also stated in: § Table 1. (Continued.) · plain
“Investigator-identified neurotoxic effects were reported in 23 patients (18%), of whom 4 (3%) had grade 3 events; no grade 4 or 5 neu-rotoxic effects were observed”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time to first response was 1.0 month (range, 0.5 to 8.8); the median time to a complete response or better was 2.8 months (range, 1.0 to 11.8).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, neurotoxic effects of any grade were reported in 0 of 4 patients, 12 of 70 patients (17%), and 11 of 54 patients (20%), respectively, with grade 3 events in 0 patients, 1 patient (1%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 54Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median overall survival was 19.4 months (95% CI, 18.2 to could not be estimated), with an overall survival of 78% at 12 months (Fig. 2D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposures were higher in patients who had a response than in those who did not (Fig. S5A), and higher exposure was associated with deeper response and longer progression-free survival (Fig. 3C and 3D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Achievement of undetectable sBCMA levels increased with depth of response (17 of 27 pa-”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, cytokine release syndrome of any grade was observed in 2 of 4 patients (50%), 53 of 70 patients (76%), and 52 of 54 patients (96%), respectively, with cytokine release syndrome of grade 3 or higher observed in 0 patients, 4 patients (6%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimate for median duration of response was 10.7 months (95% CI, 9.0 to 11.3) overall and 11.3 months (95% CI, 10.3 to 11.4) at the 450 × 10 6 dose”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher.”
- Also stated in: § Table 1. (Continued.) · plain
“Cytokine release syndrome occurred in 107 patients (84%) and was mostly of grade 1 or 2 (Table 2 and Table S10).Five patients (4%) had grade 3 cytokine release syndrome, 1 (<1%) had grade 4, and 1 (<1%) had grade 5 (300 × 10 6 dose level).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 88 patients (69%) and were of grade 3 or 4 in 28 (22%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 88Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“including many with a high tumor burden, high-risk cytogenetic abnormalities, and extramedullary disease.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After disease progression, 28 patients were retreated with ide-cel (Table S4).Six patients (21%) had a second response, with durations of response ranging from 1.9 to 6.8 months; all the patients who had a response were retreated at a dose higher than their initial dose.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most grade 3 or 4 events were hematologic toxic effects, including neutropenia in 114 patients (89%), anemia in 77 (60%), and thrombocytopenia in 67 (52%), and were at least partially related to the lymphodepleting chemotherapy administered before ide-cel infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 114Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 44 treated patients (34%) died during the study, with most deaths (27) attributed by the investigator to complications of myeloma progression (Table S12).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 44Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of proinflammatory markers, including cytokines, ferritin, and C-reactive protein, increased early after ide-cel infusion and decreased by month 1”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The response duration increased with the depth of response; the median response duration was 4.5 months (95% CI, 2.9 to 6.7), 10.4 months (95% CI, 5.1 to 11.3), and 19.0 months (95% CI, 11.3 to could not be estimated) in patients having a best response of partial response (27 patients), very good partial response (25 patients), and complete or stringent complete response (42 patients),”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the target doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, a response was observed in 2 of 4 patients (50%), in 48 of 70 patients (69%), and in 44 of 54 patients (81%), respectively, and a complete response or better was observed in 1 of 4 patients (25%), in 20 of 70 patients (29%), and in 21 of 54 patients (39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients (4%) died after 6 months from unrelated adverse events, and an additional 8 patients (6%) died after disease progression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 5Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Minimal residual disease (MRD)-negative status (<10 -5 nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better.”
- Also stated in: § Efficacy · plain
“Of the 42 patients with a complete or stringent complete response, 33 (79%) also had MRDnegative status at a sensitivity level of 10 -5 , corresponding to 26% (95% CI, 19 to 34) of the treated population; the remaining 9 patients (21%) could not be evaluated for MRD”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 33Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“High-grade hematologic toxic effects were common but transient.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites.All the patients provided written informed consent.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was performed in the population of patients treated with ide-cel (128 patients).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Between December 13, 2017, and November 13, 2018, a total of 140 patients were enrolled and underwent leukapheresis, of whom 128 received ide-cel infusions.Twelve patients discontinued the study before ide-cel infusion (including 1 patient who discontinued after unsuccessful manufacture of the CAR T-cell product)”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 140Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was designed by the authors in conjunction with the sponsors and conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size for the primary end point (overall response) was based on a onesample binomial test with normal approximation, under the assumption of 15% dropout between the time of enrollment and ide-cel treatment.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statistical tests were not performed on subgroup analyses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary end point was an overall response (partial response or better), defined according to IMWG Uniform Response Criteria for Multiple Myeloma 12 as assessed by an independent review committee.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“MRD negativity was evaluated in bone marrow aspirates by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) with a minimum cutoff of 10 -5 nucleated cells.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The actual doses delivered were within 20% of the target doses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Design and Patients
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.Cytokine release syndrome was graded according to published criteria (Table S2).14”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Soluble BCMA is a serum-based universal marker of myeloma burden.
“Soluble BCMA was assessed as a serum-based universal marker of myeloma burden.”
The paper relies on this without support.
Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
The paper relies on this without support.
MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
The paper relies on this without support.
BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
The paper relies on this without support.
The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are newly approved CAR-T products targeting BCMA that are active in relapsed refractory myeloma.89,90”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Safety of ide-cel remained consistent with the IA, with no parkinsonism, Guillain-Barré syndrome, or SPMs of T-cell origin reported. 13”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common side effects such as CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade, indicating manageable toxicity.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of response (mDOR) was 11 months in patients achieving CR and 19 months in those achieving stringent complete response (sCR).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median DOR and PFS were 10.7 months and 8.8 months, respectively, for ide-cel, and were both not reached for cilta-cel5,6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although follow-up is still ongoing, among patients with ≥CR, DOR and PFS at 15 months with elranatamab were comparable to those observed with other BCMA-targeted T-cell-redirecting therapies, suggesting similar outcomes once a deep response is achieved5,24,25.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High response rates have been reported with the BCMA chimeric antigen receptor (CAR) T-cell therapies, ide-cel and cilta-cel, with responses reported in 73% and 97% of treated patients, respectively.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.89 Thirty three percent of patients had a complete response or better. The median PFS was 8.8 months.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome was seen in 84%, and 5% were grade 3 or higher. Neurotoxicity was seen in 18%, and was grade 3 in 3%.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Chimeric antigen receptor (CAR) T-cell therapy has shown promising ef fi cacy in patients with TCE R/RMM. 13-21”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In the KarMMa study involving 128 patients with RRMM, the overall response rate (ORR) to a single infusion of Abecma was 73%, with a complete response (CR) rate of 33%.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion, providing a new and effective personalized therapy option for MM patients [227, 243, 258, 259].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Recently approved therapies such as selinexor, 9 belantamab mafodotin, 10 idecabtagene vicleucel, 11 and ciltacabtagene autoleucel 12 have had clinical benefit in patients with relapsed or refractory multiple myeloma.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [11]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 2,535
Cancer Immunotherapy Beyond Checkpoint Blockade
Welty, N. E., & Gill, S. I. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.006 · Cited by 16
Morè, S., Corvatta, L., Manieri, V. M., Olivieri, A., & Offidani, M. (2023) · British Journal of Haematology · doi:10.1111/bjh.18658 · Cited by 15
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
Yarlagadda, L. C., Gundarlapalli, S., Parikh, R., Landes, R. D., Kottarathara, M. J., Ogunsesan, Y., Hoque, S., Mitma, A. A., Bailey, C., Hill, K., et al. (2021) · Cancers · doi:10.3390/cancers13164019 · Cited by 14
“The response rates and survival outcome appear to be comparable to recent data with novel Car T cell treatment [27], suggesting that salvage ASCT constitutes a valid alternative in selected patients.”
ResultDhakal, B., Chhabra, S., Savani, B. N., & Hamadani, M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17904 · Cited by 14
Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Ray, U., & Orlowski, R. Z. (2023) · Pharmaceuticals · doi:10.3390/ph16040590 · Cited by 17
“Of further concern is the competition provided by two commercially available CAR T-cells targeting BCMA, including idecabtagene vicleucel [98] and ciltacabtagene autoleucel [99], and the BCMA bispecific teclistamab [100].”
BackgroundGuo, Z., Ding, Y., Wang, M., Zhai, Q., Liu, J., & Du, Q. (2024) · Pharmaceuticals · doi:10.3390/ph17081025 · Cited by 14
“Specifically, the complete response of patients with acute lymphoblastic leukemia (ALL) ranges from 70% to 90% [4–13], that of patients with lymphoma ranges from 50% to 70% [14–17], and that of patients with multiple myeloma (MM) ranges from 50% to 98% [18–25].”
BackgroundBispecific antibody targets and therapies in multiple myeloma
Rees, M. J., Abdallah, N., Yohannan, B., & Gonsalves, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424925 · Cited by 16
Ravi, G., Richard, S., Kumar, S. K., Atrash, S., Liedtke, M., Kaur, G., Derman, B. A., Bergsagel, P. L., Mailankody, S., McCarthy, P., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02518-5 · Cited by 15
Self-citationTonic signaling in CAR-T therapy: the lever long enough to move the planet
Huang, Y., & Wang, H. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1130-x · Cited by 17
Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer
Zhou, J. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03100-7 · Cited by 14
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Papadimitriou, M., Ahn, S., Diamond, B. T., Lee, H., McIntyre, J. B., Truger, M. S., Durante, M. A., Ziccheddu, B., Osz, K., Landgren, O., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0005 · Cited by 23
Novel immunotherapies in multiple myeloma
Ohmine, K., & Uchibori, R. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03365-1 · Cited by 13
“However, widespread BCMA-targeted therapy has led to a clinical challenge of resistance by BCMA-negative clones in the future [56].”
BackgroundResultCardiovascular disease and chimeric antigen receptor cellular therapy
Rao, A., Stewart, A. F., Eljalby, M., Ramakrishnan, P., Anderson, L. D., Awan, F. T., Chandra, A., Vallabhaneni, S., Zhang, K., & Zaha, V. G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.932347 · Cited by 13
“Management of CRS required tocilizumab in 52% patients, but only 15% required glucocorticoids (22, 63).”
BackgroundMethodInfluentialSelf-citationKikuchi, T., Tsukada, N., Nomura, M., Kasuya, Y., Oda, Y., Sato, K., Takei, T., Ogura, M., Abe, Y., Suzuki, K., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05218-1 · Cited by 11
Hu, D., Chen, L., Yan, D., Dong, W., Chen, M., Niu, S., Wang, S., Zhang, J., Nie, X., & Fang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1149138 · Cited by 13
“After a detailed evaluation of these reports, 21 studies enrolling a total of 761 participants, were considered for analysis (Alsina et al., 2020; Berdeja et al., 2021; Brudno et al., 2018; Chen et al., 2020; C. L. Costello et al., 2020; Wang et al., 2021; Du et al., 2022; Frigault et al., 2020; Green et al., 2018; Ha…”
BackgroundNew Strategies for the Treatment of Older Myeloma Patients
Larocca, A., Cani, L., Bertuglia, G., Bruno, B., & Bringhen, S. (2023) · Cancers · doi:10.3390/cancers15102693 · Cited by 14
“The phase II KarMMa study led to the approval, by the US Food and Drug Administration (FDA) and EMA, of ide–cel [89], while the phase Ib/II CARTITUDE 1 study led to the approval of cilta–cel.”
MethodImmunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies
Chen, E. C., & Garcia, J. S. (2023) · Acta Haematologica · doi:10.1159/000533990 · Cited by 13
Martínez‐López, J., Bailey, A., Lambert, A., Luke, E., Ribbands, A., Erler-Yates, N., Valluri, S., Haefliger, B., & Gay, F. (2023) · Future Oncology · doi:10.2217/fon-2023-0021 · Cited by 16
“These include, but are not limited to, the DREAMM-2 [36 , 37] , STORM [38 , 39] , HORIZON [40] , KarMMa [41] , CARTITUDE-1 [42] , MajesTEC-1 studies [43] and Talquetamab studies [43] .”
Nursing Care Throughout the Chimeric Antigen Receptor T-Cell Therapy Process for Multiple Myeloma
Steinbach, M. N., Zitella, L. J., Florendo, E., Lee, E., Riccobono, C., Difilippo, H., & Aronson, E. A. (2023) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2023.151505 · Cited by 20
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
Sadek, N. L., Costa, B. A., Nath, K., & Mailankody, S. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3057 · Cited by 13
“12,13 This may also be attributed to the lower dose used for cilta-cel, which was 10–15% the target dose for ide-cel.”
BackgroundMethodInfluentialMishra, A. K., Schmidt, T. M., Martell, E. B., Chen, A. S., Dogru, R. E., Hematti, P., & Callander, N. S. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.11.014 · Cited by 14
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
Emde, M., Beck, S., Beneš, V., Salwender, H. J., Bertsch, U., Scheid, C., Hänel, M., Weisel, K. C., Hielscher, T., Raab, M. S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286700 · Cited by 13
Self-citationBorogovac, A., & Siddiqi, T. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.001 · Cited by 14
Barata, A., Dhawale, T., Newcomb, R. A., Amonoo, H. L., Nelson, A. M., Yang, D., Karpinski, K., Holmbeck, K., Farnam, E., Frigault, M., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.01.063 · Cited by 13
CRISPR/Cas9: an overview of recent developments and applications in cancer research
Devi, S. N., Rana, R., Malik, P., & Ganguly, N. K. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001081 · Cited by 14
“Neurologic toxicities like encephalopathy and seizures were often treatable and manageable [90] .”
BackgroundNeuendorff, N. R., Khan, A., Ullrich, F., Yates, S. J., Devarakonda, S. S., Lin, R. J., von Tresckow, B., Córdoba, R., Artz, A. S., & Rosko, A. E. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.101734 · Cited by 15
FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review
Al‐Ibraheem, A., Abdlkadir, A. S., Lopci, E., Allouzi, S., Páez, D., Alkuwari, M., Ma’koseh, M., Novruzov, F., Usmani, S., Al-Rabi, K. H., et al. (2024) · Cancers · doi:10.3390/cancers16091728 · Cited by 13
“The FDA and EMA have granted approval to idecabtagene vicleucel and ciltacabtagene autoleucel in 2021 and 2022, respectively, for the treatment of r/r multiple myeloma [10,11].”
BackgroundBarbieri, E., Martino, E. A., Rivolti, E., Quaresima, M., Vigna, E., Neri, A., Morabito, F., & Gentile, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2357382 · Cited by 13
“However, no data on + 1q patients have been reported for ide-cel, neither from the phase III KarMMa-3 trial [112] nor from the phase II KarMMa trial [114].”
BackgroundThe Evolving Role of Bridging Therapy during CAR-T Therapy
Bhaskar, S., Dholaria, B., Savani, B. N., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.116261 · Cited by 13
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Parekh, D. S., Tiger, Y. K., Jamouss, K. T., Hassani, J., Zerdan, M. B., & Raza, S. (2024) · Cancers · doi:10.3390/cancers16172931 · Cited by 16
“…syndrome (CRS) is associated with all the mentioned CAR-T cell therapies and bispecific antibodies (Teclistamab, Talquetamab, Elranatamab) [17,20–22 76, 80 , Immune effector cell-associated neurotoxicity syndrome (ICANS) is another systemic immune-response-based toxicity seen with CAR-T cell…”
BackgroundInfluentialTargeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Zu, Y., Ren, Q., Zhang, J., Su, H., Lu, Q., Song, Y., & Zhou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00577-5 · Cited by 15
“Several clinical studies of anti-B-cell maturation antigen (BCMA) VHH CAR-T or CAR-NK therapies [67–69] showed similar clinical efficacy for scFv-based BCMA CAR-T therapy [70], demonstrating favorable perspectives for immuno-therapy.”
BackgroundVoynova, E., & Kovalovsky, D. (2021) · Cells · doi:10.3390/cells10112845 · Cited by 15
“Treatment shrank tumors in 72% of patients and eliminated tumors in 28% of patients that remained in remission for a median of 11 months [37].”
BackgroundStratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
Jeryczynski, G., Bolomsky, A., Agis, H., & Krauth, M. (2021) · Cancers · doi:10.3390/cancers13235886 · Cited by 13
“KarMMa 2021 [38] Ide-cel CAR T cells 2 128 ≥3, median 6 (3–16) FDA EMA ORR: total cohort 73%, ≥VGPR: 65% 300 × 106: 69%, ≥VGPR: 42% 450 × 106: 81%, ≥VGPR: 53% Total cohort: 8.”
MethodInfluentialBister, A., Ibach, T. C., Haist, C., Gerhorst, G., Smorra, D., Soldierer, M., Roellecke, K., Wagenmann, M., Scheckenbach, K., Gattermann, N., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.05.012 · Cited by 13
“To establish our NGFR-derived hinges as potential candidates for clinical use, we compared the efficacy of N3- and N4-hinged CD19 and CD33 CAR constructs to counterparts that contained a 48 aa hinge region derived from the human CD8 a-chain.45,46 Importantly, this CD8 sequence is used as the hinge in multiple CAR cons…”
MethodMarhelava, K., Krawczyk, M., Firczuk, M., & Fidyt, K. (2022) · Cells · doi:10.3390/cells11111804 · Cited by 14
“Indeed, the efficacy of idecabtagene vicleucel (Abecma) was evaluated in the pivotal KarMMa clinical trial [23].”
BackgroundMethodRoad testing new CAR design strategies in multiple myeloma
Rana, P. S., Murphy, E. V., Kort, J., & Driscoll, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957157 · Cited by 14
“In March 2021, idecabtagene vicleucel (ide-cel) was the initial BCMA–directed CAR T-cell immunotherapy approved to treat patients with RRMMbased upon results of the KarMMa study (47).”
BackgroundSpanjaart, A. M., Pennings, E. R. A., Kos, M., Mutsaers, P. G. N. J., Lugtenburg, P. J., van Meerten, T., van Doesum, J. A., Minnema, M. C., Jak, M., van Dorp, S., et al. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00501 · Cited by 14
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?
Tannoury, M., Garnier, D., Susín, S. A., & Bauvois, B. (2022) · Cancers · doi:10.3390/cancers14246026 · Cited by 13
Dib, R. W., Ariza‐Heredia, E., Spallone, A., & Chemaly, R. F. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad166 · Cited by 13
“5% in the early phase (within 30 days of CAR T-cell infusion) [14, 18– 20] and in some studies reached 58% from days 30 to 90 and 53% within 1 year during monitoring (late phase) [1, 8, 19, 21, 22].”
BackgroundZhou, L., Fu, W., Wu, S., Xu, K., Qiu, L., Xu, Y., Yan, X., Zhang, Q., Zhang, M., Wang, L., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18873 · Cited by 15
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
Shrivastava, T., van Rhee, F., & Hadidi, S. A. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s370880 · Cited by 13
“7 months.(90,91) Recently published results from KarMMA-3 (NCT03651128), involving 386 patients from 12 countries, compared ide-cel to variable regimens in patients with triple-class-refractory (66%) or daratumumab-refractory (95%) MM.”
Pan, D., & Richter, J. R. (2023) · Cancer Management and Research · doi:10.2147/cmar.s372237 · Cited by 15
“2%) failed to receive cilta-cel due to progression, withdrawal, or death.(35,36) Furthermore, an ongoing shortage of BCMA CAR-T manufacturing slots has meant that many patients who qualify for them are unable to get timely access to the products.”
BackgroundInfluentialMiller, A., Daum, R., Wang, T., Wu, M.-F., Tat, C., Pfeiffer, T., Navai, S. A., Heczey, A., Hegde, M., Ahmed, N., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.04.075 · Cited by 12
Wu, F., Zhou, J., Zheng, X., Masilamani, M., Cheng, Y., Caia, A., Cook, M. A., Piasecki, J., & Lamba, M. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01531-2 · Cited by 11
“Similar to other CAR-T therapies, ide-cel exhibited complex cellular kinetics consists of multilog initial expansion followed by rapid contraction and prolonged persistence [7, 8], which was adequately characterized by the modified piecewise model, with final model parameters summarized in Table 1.”
Sequential BCMA CAR T-cell therapy in refractory multiple myeloma
Richardson, T., Holtick, U., Frenking, J., Tharmaseelan, H., Balke-Want, H., Flümann, R., Mai, E., Sauer, S., Teipel, R., von Bonin, M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016712 · Cited by 15
Techaapornkun, P., Rojpalakorn, W., Mejun, N., Khaniya, A., Thammahong, A., Thu, M. S., Hirankarn, N., & Pitakkitnukun, P. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06524-6 · Cited by 14
“For instance, baseline extramedullary disease and R-ISS stage III were associated with poor response in more than one studies [25, 40].”
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Lee, H., Ahn, S., Gonzales, G. A., Leblay, N., Barakat, E., Greening, D., Colarusso, P., Canton, J., Benaoudia, S., Hasheminasabgorji, E., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04175-8 · Cited by 18
“Such antigenic escape mechanisms have been now well documented with anti-BCMA TCE 12,13 , and to a lesser extent post anti-BCMA CAR T 5,14,15 .”
Self-citationTargeting BCMA in Multiple Myeloma
Tan, C. R. C., & Shah, U. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00639-z · Cited by 12
Progressive multifocal leukoencephalopathy in multiple myeloma
Hoeynck, B., Cohen, A. D., Stadtmauer, E. A., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13909 · Cited by 12
“Likewise, grade 3–4 infections occurred in 22% of patients in the phase 2 study of idecabtagene vicleucel.(30) It remains uncertain whether these opportunistic infections after anti-BCMA immunotherapies reflect distinctly immunosuppressive effects of these therapies or the general immune compromise of this patient pop…”
BackgroundCombining radiotherapy and NK cell-based therapies: The time has come
Baude, J., Limagne, E., Ladjohounlou, R., & Mirjolet, C. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.02.003 · Cited by 12
Bumma, N., Dhakal, B., Fraser, R. A., Estrada‐Merly, N., Anderson, K. C., Freytes, C. O., Hildebrandt, G. C., Holmberg, L., Krem, M. M., Lee, C., et al. (2023) · Cancer · doi:10.1002/cncr.34778 · Cited by 13
Self-citationPreclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Raab, M. S., Cohen, Y. C., Schjesvold, F. H., Aardalen, K., Oka, A., Spencer, A. G., Wermke, M., Souza, A. D., Kaufman, J. L., Cafro, A. M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01883-3 · Cited by 12
“4% for cilta-cel at the approved doses [13, 14].”
BackgroundYalniz, F., Greenbaum, U., Pasvolsky, O., Milton, D. R., Kanagal‐Shamanna, R., Ramdial, J., Srour, S. A., Mehta, R. S., Alousi, A. M., Popat, U., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.06.015 · Cited by 14
Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure
Li, S., Wang, H., Guo, N., Su, B., Lambotte, O., & Zhang, T. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002904 · Cited by 11
“[10] In 18-20] T cells modified with a CAR can directly recognize CAR-targeted antigens and can then trigger T-cell activation, proliferation, cytokine secretion, and cytotoxicity to eradicate tumor cells expressing the CAR-specific antigens.”
BackgroundRauch‐Wirth, L., Renner, A., Kaygisiz, K., Weil, T., Zimmermann, L., Rodríguez, A., Schütz, D., Wiese, S., Ständker, L., Weil, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270243 · Cited by 13
“…(3), lisocabtagene maraleucel (9, 10) and brexucabtagene autoleucel (2)) and two B cell maturation antigen (BCMA)-targeted CAR-T cell products (idecabtagene vicleucel (11) and ciltacabtagene autoleucel (12)) are approved in the US and the EU by the FDA and the European Commission, respectively.”
BackgroundZhang, M., Long, X., Xiao, Y., Jin, J., Chen, C., Meng, J., Liu, W., Liu, A., & Chen, L. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007790 · Cited by 13
Motais, B., Charvátová, S., Walek, Z., Hájek, R., & Bagó, J. R. (2023) · Cells · doi:10.3390/cells12232748 · Cited by 12
“In 2021, the first anti-BCMA CAR T cell product, idecabtagene vicleucel (or Abecma), was approved by the FDA for the treatment of MM [14].”
BackgroundVisram, A., Torre, A. H. D. L., White, D., Su, J., Masih-Khan, E., Chu, M., Jimenez-Zepeda, V., Mccurdy, A., LeBlanc, R., Song, K., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00946-z · Cited by 10
Self-citationPasvolsky, O., Ghanem, S., Milton, D. R., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00973-w · Cited by 12
Next-Generation Therapies for Multiple Myeloma
Meermeier, E. W., Bergsagel, P. L., & Chesi, M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-014236 · Cited by 12
“Ide-cel was approved for the treatment of relapsed/refractory MM (RRMM) based on the data of the crucial KarMMa phase 2 trial (Munshi et al. 2021).”
BackgroundMethodInfluentialBarachini, S., Buda, G., & Petrini, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061574 · Cited by 16
“CD19-directed CAR-T are used in relapsed or refractory B-cell lymphomas and acute lymphoblastic leukemia [223], whereas B-cell maturation antigen (BCMA)-directed CAR-T are used in multiple myeloma [224].”
MethodHamadeh, I. S., Shekarkhand, T., Rueda, C., Firestone, R., Wang, A. X., Korde, N., Hultcrantz, M. L., Lesokhin, A. M., Mailankody, S., Hassoun, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012724 · Cited by 13
Puertas, B., Fernández-Sánchez, A., Alejo, E., Rey-Búa, B., Martín‐López, A. Á., López, E. P., López-Parra, M., López‐Corral, L., Gutierrez, N. C., García‐Sánz, R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012773 · Cited by 12
Roussel, M., Texier, N., Naël, V., Bitetti, J., Paka, P., Kerbouche, N., Sail, L., Colin, X., & Leleu, X. P. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14222 · Cited by 13
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Miller, K. C., Hashmi, H., & Rajeeve, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398902 · Cited by 19
“Despite remarkable ef fi cacy in R/R myeloma, it is increasingly evident that most patients with deep responses after anti-BCMA CAR T cell therapy subsequently relapse (15, 19).”
BackgroundInfluentialBeyond BCMA: newer immune targets in myeloma
Tan, M. S. Y., Chen, Y.-X., & Smith, E. L. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010856 · Cited by 12
“7,88 In the MonumenTAL-1 trial, among patients with prior exposure to T-cell redirecting therapies, ORR was 73.5% in patients with prior BCMA-targeted CAR T-cell therapy and only 47.1% in those with prior BCMA-directed TCE, further suggesting that the use of CAR T-cell therapy before consecutive…”
BackgroundInfluentialBispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
Tacchetti, P., Barbato, S., Mancuso, K., Zamagni, E., & Cavo, M. (2024) · Cancers · doi:10.3390/cancers16132337 · Cited by 16
Self-citationChabannon, C., Ruggeri, A., Montoto, S., van Biezen, A., van der Werf, S. M., Markslag, A., Sánchez‐Ortega, I., de la Cámara, R., Ljungman, P. T., Mohty, M., et al. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101557 · Cited by 15
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
Korst, C. L. B. M., O’Neill, C. A., Bruins, W. S. C., Cosovic, M., Twickler, I., Verkleij, C. P. M., Clerre, D. L., Themeli, M., Chion-Sotinel, I., Zweegman, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008769 · Cited by 13
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Yue, T., Sun, Y., Dai, Y., & Jin, F. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101256 · Cited by 15
The next innovations in chimeric antigen receptor T cell immunotherapies for cancer
Anupindi, K., Malachowski, J., Hodson, I., Zhu, D., June, C. H., & Levine, B. L. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.05.010 · Cited by 13
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency
Supper, V. M., Donner, H., Birocchi, F., Bratt, A., Escobar, G., Kann, M. C., Park, S., Martin, G., Korell, F., Takei, H., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0876 · Cited by 17
Merz, M., Gagelmann, N., Smaili, S., Flossdorf, S., Sauer, S., Scheid, C., von Tresckow, B., Wulf, G. G., Weisel, K. C., Blau, I. W., et al. (2025) · Blood · doi:10.1182/blood.2025028330 · Cited by 12
Self-citationBoosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens
Rieger, L., Irlinger, K., Füchsl, F., Tietje, M. R., Purcarea, A., Barbian, N., Faber, M., Vogelsang, C., Pfeuffer, L., Stotz, S., et al. (2025) · Blood · doi:10.1182/blood.2024027616 · Cited by 16
Self-citationSchindler-Wnek, K., Stahringer, A., Heimer, N., Koehl, U., Fricke, S., & Schmiedel, D. (2025) · Oncoimmunology · doi:10.1080/2162402x.2025.2546443 · Cited by 12
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Braunstein, M. J., Weltz, J., & Davies, F. E. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1909469 · Cited by 13
Banerjee, R. K., Fakhri, B., & Shah, N. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1924370 · Cited by 12
“ide-cel versus 7 days with cilta-cel [29,44].”
Self-citationCAR-T cell: Toxicities issues: Mechanisms and clinical management
Wallet, F., Sesques, P., Devic, P., Levrard, M., Ader, F., Friggeri, A., & Bachy, E. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.05.003 · Cited by 12
A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model
Liu, X., Zhu, M., Wang, X., Dong, X., Liu, H., Li, R., Jia, S., Lu, Q., Zhao, M., Sun, P., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01265-4 · Cited by 12
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma—Challenges and Potential Solutions
Hadidi, S. A., Zangari, M., & van Rhee, F. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0319 · Cited by 12
T-cell Immunotherapy and Cardiovascular Disease
Stein-Merlob, A. F., Ganatra, S., & Yang, E. H. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.008 · Cited by 13
Battram, A. M., Oliver‐Caldés, A., Suárez‐Lledó, M., Lozano, M., Crespo, M. B. I., Martínez‐Cibrián, N., Cid, J., Moreno, D. F., Rodríguez‐Lobato, L. G., Urbano-Ispizúa, Á., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.010 · Cited by 12
“9 18 Analysis of the parameters that in fl uence the ef fi cacy of one anti-BCMA CAR-T cell product revealed that some of these factors, particularly fewer CD8 + early differentiated (CD45RO (cid:1) CD27 + ) cells and a lower CD4:CD8 ratio in the starting T cell product, were associated with a poorer…”
BackgroundInnovation in BCMA CAR-T therapy: Building beyond the Model T
Banerjee, R. K., Lee, S. S., & Cowan, A. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1070353 · Cited by 12
“0 million viable CAR-T cells per kilogram of body weight (6, 13).”
BackgroundInfluentialOff-the-shelf CAR T cells for multiple myeloma
Brudno, J. N., & Kochenderfer, J. N. (2023) · Nature Medicine · doi:10.1038/s41591-022-02195-2 · Cited by 12
Granger, K., Gaffney, K. J., & Davis, J. A. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231154809 · Cited by 14
“Approval for these agents was based on the results of the KarMMa and CARTITUDE-1 trials.(8,9)”
MethodMasilamani, M., Jawa, V., Dai, Y., Das, R., Park, A., Lamba, M., Wu, F., Zheng, X., Lu, E., Gleason, C. R., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2991 · Cited by 13
“During early stage of idecel clinical development, two idecel clinical studies (CRB- 401, a phase I study and KarMMa, a phase II study in subjects with multiple myeloma) have used a validated realtime qPCR to amplify DNA from whole blood derived CD3 cells for quantification of transgene copies as a measure for cellula…”
Multiple Myeloma in 2023 Ways: From Trials to Real Life
Fazio, M., Fabro, V. D., Parrinello, N. L., Allegra, A., Markovic, U., Botta, C., Accardi, F., Vincelli, I. D., Leotta, S., Elia, F., et al. (2023) · Current Oncology · doi:10.3390/curroncol30110705 · Cited by 14
“Twenty-eight patients experienced a disease progression and were retreated with Ide-cel at a higher dose, reaching a second response with a duration of 1.9–6.8 months [76].”
InfluentialBCMA CAR-T cells in multiple myeloma–ready for take-off?
Scheller, L., Tebuka, E., Rambau, P., Einsele, H., Hudecek, M., Prommersberger, S., & Danhof, S. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2276676 · Cited by 14
“…of the aforementioned trial led to initiation of the KarMMa trial (Nct03361748), a phase-ii study to further evaluate the efficacy and safety of bb2121 in patients with relapsed/refractory MM (rrMM) after at least three previous regimens including a Pi, an iMiD, and an anti-cD38 mAb [22] (table 1).”
Self-citationThe role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
Oriol, A., Abril, L., Torrent, A., Ibarra, G., & Ribera, J. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211019622 · Cited by 14
Self-citationThe emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma
Davis, J. A., Shockley, A., & Hashmi, H. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211073517 · Cited by 12
“The median time to onset of CRS was 1 day (1-12), with a median duration of 5 days (1-63).”
BackgroundCAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuitPreprint
Yi, F., Cohen, T., Zimmerman, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.26.582108 · Cited by 12
Ishida, T., Kuroda, Y., Matsue, K., Komeno, T., Ishiguro, T., Ishikawa, J., Ito, T., Kosugi, H., Sunami, K., Nishikawa, K., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03884-z · Cited by 13
“The most common hematologic TEAEs observed in this study were neutropenia, lymphopenia, and anemia; this was comparable with the global MajesTEC-1 study [12, 20, 21].”
Besliu, C., Tănase, A., Rotaru, I., Espinoza, J., Vidal, L., Poelman, M., Juan, M., de Larrea, C. F., & Saini, K. S. (2025) · Cancers · doi:10.3390/cancers17030525 · Cited by 15
“…six prior treatment lines; a total of 26% of patients in the KarMMa study and 42% of patients in the CARTITUDE-1 study being penta-drug refractory), with a CR/sCR rate of 33% in the KarMMa study, an 82.5% sCR rate in the CARTITUDE-1 study, and improved PFS and overall survival [64,66–68] (Table 2).”
InfluentialFortuna, G. G., Peres, L. C., Назаренко, Е. Б., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016966 · Cited by 11
“37,38 In a recent single-center retrospective analysis, 85% of patients who received BCMA-directed CAR T-cell therapy developed an infection complication, with viral infections being the most common etiology of these events (40%).”
Self-citationMechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 14
“Antigen escape can also occur following treatment with anti-BCMA CAR T-cells, although BCMA-negative clonal relapses appear less frequent, occurring in fewer than 5% of cases compared to the 9–24% reported in B-ALL and 20–27% in B-NHL patients [4,5,19,47–49].”
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape
Sezer, E., Lee, S., & Chung, J. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.12.004 · Cited by 11
The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
Alomari, M., Kunacheewa, C., & Manasanch, E. E. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2133540 · Cited by 11
Phase I CAR-T Clinical Trials Review
Bulsara, S., Wu, M.-F., & Wang, T. (2022) · Anticancer Research · doi:10.21873/anticanres.16076 · Cited by 11
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
Chatwal, M. S., Chahoud, J., & Spiess, P. E. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.09 · Cited by 12
Tyczyńska, A., Krzempek, M., Cortez, A., Jurczyszyn, A., Godlewska, K., Ciepłuch, H., Subocz, E., Hałka, J., de Nałęcz, A. K., Wiśniewska, A., et al. (2023) · Cancers · doi:10.3390/cancers15133469 · Cited by 11
“The safety data are so far optimistic and demonstrate acceptable rates of Grade 3 and 4 events [24,25], which suggests that this therapy might be also considered in elderly patients, without any age limit, after prior careful selection in order to prevent possible adverse events.”
Background
Metadata
- Authors
- Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K., & San-Miguel, J.
- Affiliations
- Harvard University (US)
- Mayo Clinic (US)
- Hackensack University Medical Center (US)
- From the Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute (N.C.M.), the Veterans Affairs Boston Healthcare System, Harvard Medical School (N.C.M.), and Massachusetts General Hospital (N.R.), Boston, and bluebird bio, Cambridge (F.P., M.M.) — all in Massachusetts; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.); the University of California, San Francisco, San Francisco (N.S.); Icahn School of Medicine at Mount Sinai, New York ...
- ORCID
- Munshi, Nikhil C.
- Anderson, Larry D.
- Shah, Nina
- Madduri, Deepu
- Berdeja, Jesús
- Lonial, Sagar
- Raje, Noopur
- Lin, Yi
- Siegel, David
- Oriol, Albert
- Moreau, Philippe
- Yakoub-Agha, Ibrahim
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Rambaldi, Alessandro
- Reece, Donna
- Petrocca, Fabio
- Connarn, Jamie N.
- Kaiser, Shari
- Patel, Payal
- Huang, Liping
- Campbell, Timothy B.
- Hege, Kristen
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 705-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3133229959
- Semantic Scholar
- fd96e2f87dff7d1153a17b78b56fbbab69cb714e
- Cited by
- 2,560
- References
- 17
- Citations by year
- 2026: 411 · 2025: 486 · 2024: 540 · 2023: 493 · 2022: 436 · 2021: 186
- FWCI
- 150.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- idecabtagene vicleucel, CAR T-cell therapy, relapsed/refractory multiple myeloma, BCMA, minimal residual disease, cytokine release syndrome, neurotoxicity, CAR T cell persistence, progression-free survival, complete response, neutropenia, anemia, thrombocytopenia, chimeric antigen receptor T cells
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Cytokine Release Syndrome, Adult, Aged, Female, Hematologic Diseases, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Biomarkers, Immunotherapy, Adoptive, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
